THERAVANCE BIOPHARMA INC (TBPH:NASDAQ)
$16.35 -0.2 (-1.2085%)
Analysed THERAVANCE BIOPHARMA INC (TBPH:NASDAQ) News Sources
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics
06-04-2026
yahoo.com
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
02-04-2026
yahoo.com
Theravance's Q4 Earnings and Revenues Miss Estimates
20-03-2026
yahoo.com
All You Need to Know About Theravance Bio (TBPH) Rating Upgrade to Strong Buy
20-03-2026
yahoo.com
Theravance Biopharma (TBPH) Q4 Earnings and Revenues Lag Estimates
19-03-2026
yahoo.com
Theravance Bio: Q4 Earnings Snapshot
19-03-2026
yahoo.com
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
19-03-2026
yahoo.com
Assertio (ASRT) Reports Q4 Loss, Beats Revenue Estimates
16-03-2026
yahoo.com
How The Theravance Biopharma (TBPH) Story Is Reset Around Respiratory Assets And Cash
11-03-2026
yahoo.com
Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH)
09-03-2026
yahoo.com
What is the current price of THERAVANCE BIOPHARMA INC (TBPH:NASDAQ)?
The current price of THERAVANCE BIOPHARMA INC (TBPH:NASDAQ) is $16.35.
THERAVANCE BIOPHARMA INC (TBPH:NASDAQ) absolute price change since previous trading day?
The absolute price change of THERAVANCE BIOPHARMA INC (TBPH:NASDAQ) since the previous trading day is $-0.2.
THERAVANCE BIOPHARMA INC (TBPH:NASDAQ) percentage price change since previous trading day?
The percentage price change of THERAVANCE BIOPHARMA INC (TBPH:NASDAQ) since the previous trading day is -1.2085%.
What is the most recent average sentiment score for THERAVANCE BIOPHARMA INC (TBPH:NASDAQ)?
The most recent average sentiment score for THERAVANCE BIOPHARMA INC (TBPH:NASDAQ) is 54 out of 100.
What is the most recent average sentiment for THERAVANCE BIOPHARMA INC (TBPH:NASDAQ)?
The most recent sentiment for THERAVANCE BIOPHARMA INC (TBPH:NASDAQ) is .
SEC-8K** Filing Available For THERAVANCE BIOPHARMA INC (TBPH:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.